Salute e Benessere
Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Dr. David N. Cade , Telix Group Chief Medical Officer, said, "We are pleased to be able to so comprehensively showcase our pipeline at EANM – the largest gathering of nuclear medicine professionals worldwide – with a sponsored symposium, and abstracts accepted across Telix's late-stage theranostic programs in kidney and brain cancers, and in bone marrow conditioning. As in previous years, it is an honour for us to support the EANM Sanjiv Sam Gambhir Young Investigator Award. This is an exciting opportunity for a junior physician or scientist to further develop their career in radiopharmaceuticals, in memory of an extraordinary man and an inspiring educator."
We look forward to seeing delegates at Telix's booth in Hall H, Stand H29 to discuss Telix's industry leading theranostic pipeline in urologic oncology (prostate, kidney and bladder cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and hematology, our associated medical devices, and opportunities for collaboration.
Professor Viktor Grünwald, University Hospital Essen, Essen, Germany .
Unravelling radiobiological and immunological mechanisms driving effective CAIX-TRT and ICI combination therapy
S. Kleinendorst, RadboudUMC, Netherlands
20-Oct-24, 08:00 – 09:30
Cutting Edge Science Track - TROP Session: Dosimetry Committee: Preclinic and Radiobiology
Oral
Hall Y4 - Y9
OP-022
Accuracy of personalised single time point dosimetry for bone marrow and liver dosimetry in TLX66 ( Y-Anti CD66) radioimmunotherapy
A. Nautiyal, University Hospital Southampton, United Kingdom
20-Oct-24, 15:00 – 16:30
Cutting Edge Science Track - TROP Session: Dosimetry Committee: Dosimetry: A Question of Time
Oral
Hall Y4 - Y9
OP-158
Tumour margin thickness inference for Tc radio-guided surgery using internal conversion electrons
J. Moo, Telix
21-Oct-24, 08:00 – 09:30
Cutting Edge Science Track - TROP Session: Physics Committee: Data Corrections / Image Enhancement
Oral
Hall Y4 - Y9
OP-289
Radiation protection considerations with TLX250-CDx ( Zr-girentuximab) PET/CT experience in
France
C. Morgat, Department of Nuclear Medicine, University Hospital of
Bordeaux, France
21-Oct-24, 15:00 – 16:30
TROP Session: Radiation Protection Committee: Radiation Protection in Diagnostic Imaging Procedures
Oral
Hall Y1 - Y3
OP-452
Correlation of tracer uptake in sentinel lymph nodes as measured on SPECT/CT and during intraoperative gamma tracing with the SENSEI drop in gamma probe: the UZ Leuven experience
M. Manley, Nuclear Medicine, University Hospitals Leuven,
Belgium
22-Oct-24, 08:00 – 09:30
Cutting Edge Science Track – TROP Session: Physics Committee: SPECT/CT Quantification
Oral
Hall Y4 - Y9
OP-543
Development of Tb-DOTA-HYNIC-panPSMA for targeted radionuclide therapy of prostate Cancer
C. Morgat, Department of Nuclear Medicine, University Hospital of
Bordeaux, France
22-Oct-24, 08:00 – 09:30
M2M Track - TROP Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: From Radionuclide to Clinical Translation
Oral
Hall X1-X4
OP-532
Feasibility and tolerability of TLX101 (¹³¹I-IPA) monotherapy in progressive and recurrent high grade gliomas; an ongoing single institution case series
N. Tolboom, University Medical Centre
Utrecht, Netherlands
22-Oct-24, 16:45 – 18:15
TROP Session: Neuroimaging Committee: Neuro-Oncology
Oral
Hall Y10 - Y12
OP-758
The emerging role of TLX250-CDx ( Zr-girentuximab) PET/CT in accurate characterisation and staging of ccRCC: early experience with three patients
F. Gelardi, Università Vita-Salute San Raffaele,
Italy
23-Oct-24, 08:00 – 09:30
TROP Session: Case Report Session 2: You Won't Believe the Things I've Seen!
Oral
Hall Y1 - Y3
OP-824
Development of girentuximab as a theranostic tool in non-renal indications
A. Ivashkevich, Telix
23-Oct-24, 08:00 – 09:30
e-Poster Presentations Session 13: Translational Molecular Imaging & Therapy Committee: Molecular Imaging & Therapy
Oral ePoster
Hall F
EPS-270
Preclinical evaluation of DNA damage response inhibitors and TLX252 ( Ac-DOTA-girentuximab) combination therapy
Z. Cao, Olivia Newton-John Cancer Research Institute,
Australia
23-Oct-24, 08:00 – 09:30
e-Poster Presentations Session 13: Translational Molecular Imaging & Therapy Committee: Molecular Imaging & Therapy
Oral ePoster
Hall F
EPS-269
Development of Kit-Composition for the Preparation of Tc-PSMA-GCK01 / RHN001-Dx
J. Cardinale, University Hospital Duesseldorf, Germany
D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control
e-Poster
e-Poster Area
EP-1037
Development of F-labelled lactate for oxidative cancer imaging
M. da Silva Morais , Pole of Pharmacology, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain),
Belgium
D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D55 Radiopharmacokinetics and Drug Development
e-Poster
e-Poster Area
EP-1010
Radiolabelling DOTA-HYNIC-panPSMA with actinium-225 for in vivo studies
K. Attia, Telix
D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D53 New Radiopharmaceuticals - Therapy
e-Poster
e-Poster Area
EP-0985
Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Telix's lead imaging product, gallium-68 ( Ga) gozetotide injection (also known as Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA) , by the Australian Therapeutic Goods Administration (TGA) , and by Health Canada . No other Telix product has received a marketing authorisation in any jurisdiction.
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn .
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Legal Notices
View original content: https://www.prnewswire.co.uk/news-releases/telix-featured-in-13-abstracts-at-the-annual-congress-of-the-european-association-of-nuclear-medicine-eanm-302277605.html